STOCK TITAN

Halozyme Therapeutics Inc. - HALO STOCK NEWS

Welcome to our dedicated news page for Halozyme Therapeutics (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Halozyme Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Halozyme Therapeutics's position in the market.

-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
conferences earnings
Halozyme Therapeutics Inc.

Nasdaq:HALO

HALO Rankings

HALO Stock Data

5.17B
125.48M
1.07%
100.11%
6.37%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
San Diego

About HALO

we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies